Updated August 2026

Quetiapine

Brand name - Seroquel

Oral dosing for schizophrenia in adults

Quetiapine is a second-generation antipsychotic used to treat schizophrenia. Its exact therapeutic mechanism is unclear, but may be mediated by antagonism at dopamine D2 and serotonin 5-HT2A receptors.

Dosing guidance is outlined in the table to the right.

	Extended Release	Immediate Release
Initial Dose	300mg	25mg bid
Titration Timeline	Increase by 100 mg/day as tolerated and indicated	Increase by 25-50 mg/day as tolerated and indicated
Target - **Max** Dose	400 - **800**mg/day	150 - **750**mg/day

Prescribing Pearls

- **Monitor blood pressure, weight/BMI, A1c, and lipids** before and throughout treatment. Ask about increased appetite and hyperglycemia symptoms.
- **Assess** extrapyramidal symptoms, tardive dyskinesia, orthostatis, falls, substantial weight gain, somnolence, signs of hyperprolactinemia, and anticholinergic side effects.
- **Sedation is common.** Nighttime dosing preferred if taking once daily.
- **Consider thyroid assessment** when indicated, such as long-term treatment or symptoms suggesting thyroid dysfunction.
- Review CYP3A4 interactions. Strong CYP3A4 inhibitors can substantially increase quetiapine exposure, while strong CYP3A4 inducers can reduce exposure. Dose adjustment may be required; consult current product-specific labelling.
- **Alcohol or hypotensive agents** may worsen somnolence or orthostatic symptoms.
- **To stop or change treatment**, individualize taper and monitor for recurrence. Serious adverse reactions may require more urgent discontinuation.

Safety

- Consider a lower initial dose, slower titration for patients who are debilitated, older, predisposed to hypotension, pharmacodynamically sensitive, or have hepatic impairment.
- **Pregnancy and lactation.** Use individualized risk-benefit analysis. Available human data have not established a drug-associated increase in major birth defects, miscarriage, or adverse maternal or fetal outcomes. **Untreated schizophrenia and psychosis carry substantial maternal and perinatal risks.** Third-trimester antipsychotic exposure may cause neonatal extrapyramidal or withdrawal symptoms; monitor exposed neonates.
- Review QT-prolonging medications and major risk factors; ECG monitoring is based on clinical risk rather than routinely required for all patients.
- Urgent evaluation: Fever with rigidity or confusion, autonomic instability, allergic reaction, syncope, sever hyperglycemia, or rapidly developing abnormal movements.
- Prompt assessment: Severe akathisia, new involuntary movements, marked hyperglycemia symptoms, rapid weight gain, marked sedation, severe constipation, significant orthostasis.
- Driving and hazardous activity: use caution until the individual response to sedation and cognitive or motor effects is known.
- Monitor CBC more closely in patients with a history of low WBC or drug-induced leukopenia/neutropenia.

Dementia-related psychosis. Not approved for this indication. Antipsychotic treatment is associated with increased mortality in older adults with dementia-related psychosis and carries a black box warning.

Disclaimer

Indiana CHAMP is a resource hub and consultation service to supplement clinician decision-making. The information on this sheet does not constitute medical care. The clinician is responsible for ensuring appropriate application of guidance in patient care.